New Tapinarof Data Released

Dermavant had patient satisfaction data from the PSOARING 3 long term extension trial presented at the 2022 Winter Clinical Dermatology Conference.

Dermavant Sciences, a biopharmaceutical company, announced results from a patient satisfaction questionnaire in the long-term, open-label phase 3 PSOARING 3 (NCT04053387) extension study of tapinarof cream 1% (Dermavant Sciences), an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, as a once daily for the treatment of plaque psoriasis in adult patients.1

It was found from the patient responses that there were consistent high rates of satisfaction and positive perception of treatment with tapinarof across all patient-relevant parameters—like satisfaction of efficacy, formulation elegance, application ease, impact on daily life, and tapinarof preference. These results were presented during the 2022 Winter Clinical Dermatology Conference, held January 14-19, in Kauai, Hawaii.

“As a clinician, it’s paramount that my patients are satisfied with their treatment, as research shows that patients who are satisfied with their treatment are more likely to continue treatment, which may improve treatment efficacy,” said Jerry Bagel, MD, MS, director of the Psoriasis Treatment Center of New Jersey and Eczema Treatment Center of New Jersey in East Windsor, a member of the National Psoriasis Foundation board of directors, and lead author of the publication. “I am encouraged by these results with tapinarof showing consistent patient satisfaction, which has often been difficult to achieve with current psoriasis treatments, including steroidal topicals. Building on previous PSOARING 3 results, these findings demonstrate that tapinarof, subject to FDA approval, has the potential to be a long-awaited new treatment option to improve the care of patients suffering from this debilitating, chronic condition.”

The responses were collected at study completion, which could be at week 40 or at early termination, demonstrated consistent high rates of satisfaction across all evaluated parameters. There were 599 patients or 78.5% of patients that completed the survey and of that amount it was found:

  • Patients preferred tapinarof to prior topical treatments with 81.7% considering it more effective.
  • 85.8% either strongly agreed or agreed they could easily manage their psoriasis with tapinarof.
  • 82.5% expressed that they would use tapinarof again or continue using it if available.

“As a team that is driven by a passion for helping patients, we are delighted to present findings for patient satisfaction with tapinarof from PSOARING 3 during the 2022 Winter Clinical Dermatology Conference, highlighting our continued commitment to addressing unmet needs for patients with inflammatory skin conditions,” said Philip M. Brown, MD, JD, chief medical officer of Dermavant. “We know that patients with plaque psoriasis and their physicians are looking for non-steroidal topical treatment options, and we hope to bring long-overdue innovation to this community.”

The FDA has accepted the New Drug Application (NDA) for tapinarof as a treatment for plaque psoriasis in adults and set the PDUFA target action date to Q2 2022.

Reference:

1. Dermavant presents new patient satisfaction data from PSOARING 3 long term extension trial of Tapinarof in adults with plaque psoriasis at the 2022 Winter Clinical Dermatology Conference. Dermavant Sciences. Published January 15, 2022. Accessed January 17, 2022. https://www.dermavant.com/dermavant-presents-new-patient-satisfaction-data-from-psoaring-3-long-term-extension-trial-of-tapinarof-in-adults-with-plaque-psoriasis-at-the-2022-winter-clinical-dermatology-conference/